Canadian drugmaker Valeant Pharmaceuticals said Friday it will increase the list prices of products in some of its portfolios by 2 percent to 9 percent. » Read More
Singapore Breast Cancer Foundation's Noor Quek talks about the importance of early detection through screenings.
New non-invasive tests are helping doctors better diagnose what stage prostate cancer patients have so they can forgo risky biopsies.
Chinese pollution has become such a problem that it has actually become an unexpected moneymaker for some large companies.
Google has teamed up with DexCom to develop smaller, cloud-enabled glucose monitors that may replace finger pricks.
The FDA approves a non-surgical device for treating obesity.
Three-D printing could make life a lot easier and affordable for some, Autodesk's Andreas Bastian says.
Ebola briefly returned to the headlines this week with a scare at a hospital in New York, but the deadly virus continues to claim victims in West Africa.
A man bitten by a rattlesnake this month says he received a $153,000 hospital bill.
Andy Slavitt, the acting boss of the Centers for Medicare and Medicaid Services, which oversees Obamacare, has been nominated as head of the agency.
The CEO of Medtronic talks new FDA approval and how to improve the health-care system.
Bad news has been a boon for Malaysia's rubber glove makers, with the ringgit's drop and South Korea's MERS outbreak likely to provide a twin boost.
Anthem has disclosed that a database containing personal information for about 80 million of its customers and employees was hacked, CNBC has confirmed.
Cathrin Petty, co-head of EMEA healthcare at JP Morgan, says the U.K. has the capacity to be a successful market for life sciences, and the year ahead for healthcare IPOs looks strong.
Dan Mahony, fund manager at Polar Capital, tells CNBC how to be a "smart healthcare investor".
The ability to unfold a protein and return it to its original state could save money in everything from cancer research to food production.
Scientists have developed a glucose monitor that is about as invasive as a rub-on tattoo.
Get the best of CNBC in your inbox